Fully Replicate Study [Study As­sess­ment]

posted by NK – India, 2021-04-26 11:46 (1176 d 18:25 ago) – Posting: # 22323
Views: 3,415

Dear All,

We did BE study (both fasting and fed) for ER formulation of a drug (HVD), with fully replicated design (RTRT/TRTR) for USFDA. The protocol says, plasma samples from subjects who complete all the four periods will be analyzed and will be included for PK and statistical analysis.

Where we observed following:Can we include Subject A & B for statistical analysis (protocol not specified about handling subject with three periods data. (ie. one T & two R and one R & Two T).

To handle this kind of situation in future, Can we mention in the protocol to exclude the subject (outlier) with above scenario.

Thanks in advance

Regards
NK


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,101 posts in 4,857 threads, 1,644 registered users;
80 visitors (0 registered, 80 guests [including 8 identified bots]).
Forum time: 06:11 CEST (Europe/Vienna)

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5